Geneart expands in Gewerbepark Regensburg
Geneart produces artificial genes as a key technology for new therapeutics and vaccines. Since entering the market eight years ago the company has doubled its capacity annually. Currently the company produces up to two million base pairs per month, which corresponds to 2,000 genes. The turnover last rose by 60% to 3.9 million € in the 1st quarter 2008. Further large contracts, such as recently with the American Health Authority (NIH) to the amount of 1.9 million €, have therefore made it necessary for further structural growth. The company founded in 1999 from the University of Regensburg has a meteoric rapid rise to world market leader in the area of gene synthesis behind it. The company moved to BioPark I in Regensburg in 2000 with 8 employees on 200 m2. Promoted by the City of Regensburg the company was able to develop dynamically. Upon relocation in BioPark II in 2006 there were already 68 employees working in 2,200 m2 of office and laboratory space. In May 2006 Geneart was listed successfully on the Frankfurt Stock Exchange. Today with almost 200 employees and a strong growth rate Geneart has set the course for further expansion in Gewerbepark Regensburg. “It is an exceptional pleasure for me that one of the first companies from the BioPark has become so successfully “fully fledged” and demonstrates the possible success for a Biotech company in Germany”, commented the Managing Director of BioPark Regensburg GmbH Dr. Thomas Diefenthal on this milestone.
For more information see: